Skip to content
Medxy AI
  • Wellness & Lifestyle
  • Clinical Updates
  • Medical News
  • Wellness & Lifestyle
  • Clinical Updates
  • Medical News
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
Subscribe
  • Home
  • ADC
Dupilumab as a Steroid-Sparing Strategy for ADC-Induced Skin Toxicities: Enhancing Cancer Therapy Continuity
Posted inClinical Updates Wellness & Lifestyle

Dupilumab as a Steroid-Sparing Strategy for ADC-Induced Skin Toxicities: Enhancing Cancer Therapy Continuity

Posted by By MedXY 07/31/2025
Dupilumab controls ADC-related skin toxicities more effectively than systemic steroids, reducing cancer treatment discontinuation and improving response rates.
Read More
  • Efficacy and Safety of 5 mg Olanzapine Added to Standard Antiemetics for Breast Cancer Chemotherapy: Insights from a Phase 3 Double-Blind Trial
  • Subcutaneous Blinatumomab in Relapsed/Refractory B-ALL: Clinical Promise and the Future of Delivery Modalities
  • Cabozantinib Plus Atezolizumab in mCRPC: CONTACT-02 Phase 3 Final Results and Clinical Implications
  • Impact of Maternal Pertussis Vaccination on Infant Immune Responses: Insights from the GaPS Trial in The Gambia
  • Individualised Versus Standard 10-Day Antibiotic Therapy in Pediatric Febrile UTI: Insights from the INDI-UTI Trial
  • About us
  • Contact us
  • Privacy Policy
  • Subscribe Now!
  • English
  • 日本語
  • Tiếng Việt
  • 中文

aging Alzheimer's disease Antibiotics breast cancer clinical trial clinical trials diabetes diagnosis diet epidemiology exercise FDA FDA approval GLP-1 health healthcare Hypertension immunotherapy lifestyle lifestyle intervention longevity maternal health men's health Menopause mental health nutrition obesity older adults PCOS Physical Activity Pregnancy prevention public health randomized trial semaglutide sexual health sleep stroke treatment type 2 diabetes Vaccine walking weight loss wellness women's health

Your health, we care

Copyright 2025 — Medxy AI. All rights reserved.
Scroll to Top